Vectura Forays into China by Forming JV with Tianjin KingYork and Zendex Bio Strategy
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 5 (Table of Contents)
Published: 25 May-2013
DOI: 10.3833/pdr.v2013.i5.1943 ISSN: 1756-7874
Section: Joint Venture
Fulltext:
Abstract
In order to access fast growing Asian respiratory markets, UK-based Vectura has formed a joint venture (JV) with Tianjin KingYork, a Chinese pharmaceutical company and specialist manufacturer of corticosteroid-based products, and Zendex Bio Strategy, a Hong Kong-based private equity investor...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS